Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Celularity's acquisition of the assets of the company
|
| gptkbp:awards |
Various industry awards
|
| gptkbp:business_model |
Cell therapy commercialization
|
| gptkbp:ceo |
gptkb:Robert_Hariri
|
| gptkbp:clinical_trial |
Ongoing
Phase 1 and Phase 2 trials |
| gptkbp:collaborations |
Academic institutions
|
| gptkbp:community_engagement |
Active in local communities
|
| gptkbp:conference |
Participates in industry conferences
|
| gptkbp:financial_performance |
Publicly reported financials
|
| gptkbp:focus |
Cell therapy
|
| gptkbp:founded |
gptkb:2016
|
| gptkbp:founder |
gptkb:Bob_Hariri
|
| gptkbp:future_plans |
Increase production capacity
Expand into new markets Enhance technology platform Develop new therapies Broaden research collaborations |
| gptkbp:headcount |
Over 100 employees
|
| gptkbp:headquarters |
gptkb:New_Jersey
|
| https://www.w3.org/2000/01/rdf-schema#label |
Celularity Inc.
|
| gptkbp:industry |
gptkb:Company
|
| gptkbp:invention |
Multiple patents granted
|
| gptkbp:investment |
Various venture capital firms
Funding from private equity |
| gptkbp:leadership |
Experienced management team
|
| gptkbp:market |
Global biotechnology market
|
| gptkbp:mission |
Transforming the treatment of disease
|
| gptkbp:partnership |
gptkb:United_Therapeutics
Pharmaceutical companies |
| gptkbp:products |
gptkb:Allo_Stim
gptkb:CYNK-001 Cure D |
| gptkbp:publishes |
Numerous publications in journals
|
| gptkbp:receives_funding_from |
Initial public offering in 2018
|
| gptkbp:regulatory_compliance |
FDA approved products
|
| gptkbp:research_and_development |
Significant investment
|
| gptkbp:research_focus |
Cancer treatment
Autoimmune diseases Infectious diseases Placental-derived cells |
| gptkbp:social_responsibility |
Commitment to ethical practices
|
| gptkbp:strategic_importance |
Increase market share
Strengthen partnerships Enhance research capabilities Achieve profitability Expand product pipeline |
| gptkbp:subsidiary |
gptkb:Celularity_Therapeutics
|
| gptkbp:symbol |
CELU
|
| gptkbp:technology |
Cellular immunotherapy
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:vision |
Innovative cell-based therapies
|
| gptkbp:website |
www.celularity.com
|
| gptkbp:bfsParent |
gptkb:Sorrento_Therapeutics
|
| gptkbp:bfsLayer |
5
|